Safety and immunogenicity of a 2-dose Ebola vaccine regimen with Ad26.ZEBOV and MVA-BN-Filo in a Phase III clinical trial in Sierra Leone

Архивировано 04.10.2021: escmid-2019-O1059.pdf

Источник: Leigh B., et al. Safety and immunogenicity of a 2-dose Ebola vaccine regimen with Ad26.ZEBOV and MVA-BN-Filo in a Phase III clinical trial in Sierra Leone. ESCMID, 2019, O1059

The Ad26, MVA (0, 56) vaccine regimen was well tolerated in adults in a country previously affected by Ebola. Robust and persistent immune responses to the vaccine regimen were observed. Ad26, MVA vaccine regimens may be suitable for vaccination strategies in countries susceptible to Ebola outbreaks.